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Abstract: The ubiquitin-proteasome pathway (UPP) is the central protein degradation system in
eukaryotic cells, playing a key role in homeostasis maintenance, through proteolysis of regulatory
and misfolded (potentially harmful) proteins. As cancer cells produce proteins inducing cell proliferation
and inhibiting cell death pathways, UPP inhibition has been exploited as an anticancer strategy to shift
the balance between protein synthesis and degradation towards cell death. Over the last few years,
marine invertebrates and microorganisms have shown to be an unexhaustive factory of secondary
metabolites targeting the UPP. These chemically intriguing compounds can inspire clinical development
of novel antitumor drugs to cope with the incessant outbreak of side effects and resistance mechanisms
induced by currently approved proteasome inhibitors (e.g., bortezomib). In this review, we report
about (a) the role of the UPP in anticancer therapy, (b) chemical and biological properties of UPP
inhibitors from marine sources discovered in the last decade, (c) high-throughput screening techniques
for mining natural UPP inhibitors in organic extracts. Moreover, we will tell about the fascinating story
of salinosporamide A, the first marine natural product to access clinical trials as a proteasome inhibitor
for cancer treatment.
Keywords: natural products; ubiquitin; proteasome; marine; salinosporamide; cancer; high-throughput
screening; secondary metabolites; lead compounds
1. Introduction
Natural products (often referred to as secondary metabolites) have a long history as therapeutics
for treatment of human diseases, including cancer. So far, most of the anticancer drugs currently
used in therapy can be traced back to natural products (NPs), with the most striking examples being
represented by terrestrial plant- or microbe-derived secondary metabolites such as vinblastine, taxol,
and doxorubicin. More recently, chemical investigations of aquatic ecosystems (seas, oceans, lakes)
have added novel chemical structures featuring antitumor properties. The great majority of these
compounds were isolated from marine invertebrates, such as sponges, bryozoans, ascidians, and soft
corals [1,2]. In particular, cytarabine, eribulin mesylate, trabectidin and brentuximab vedotin are either
genuine marine NPs or marine natural product-derivatives, which are currently included in clinical
settings for cancer treatment [3]. Moreover, 12 marine drugs are in different phases of clinical trials for
clinical evaluation against different types of malignancies [4].
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Drug development of natural lead compounds finds a limiting-step in the reduced access to
enough quantities of pure compounds (the so-called supply problem), as secondary metabolites
are usually produced in trace-amounts by marine organisms. The observation that many of these
bioactive compounds are produced by associated microorganisms rather than the original source has
moved attention towards exploration of the symbiotic microbiome, thereby leading to identification
of microbial producers of bioactive molecules [5–7]. In parallel, researchers focused on the chemical
profiling of free-living marine bacteria (mainly actinobacteria and cyanobacteria) and fungi, which are
emerging as a sustainable ‘factory’ of natural products to fuel their clinical development [8,9].
Cancer cells are known to produce proteins, which are able to block cell-death pathways and/or
induce cell proliferation and survival. With the discovery in the 1980s of the ubiquitin-proteasome
pathway (UPP) as the central regulator of the intracellular-protein degradation machinery, preclinical,
and clinical studies have explored proteasome inhibitors as anticancer drugs to shift the protein
turnover towards cell-death [10]. Successful clinical trials led to Food and Drug Administration (FDA)
approval of bortezomib, a first-generation proteasome inhibitor, and later to that of second-generation
agents, including carfilzomib and ixazomib [10]. Notably, carfilzomib is an irreversible proteasome
inhibitor inspired to epoxomicin, a naturally occurring peptidyl epoxyketone isolated from the
Actinomycetes strain Q996-17 [11].
The UPP is an evolutionary well conserved pathway across eukaryotic species. It is well known
that pathogenic bacteria have developed, among other strategies, the ability of producing secondary
metabolites, to subvert and manipulate the host ubiquitin-proteasome system for their own benefits.
Indeed, accumulating evidence suggests that bacteria produce proteasome inhibitors as virulence
factors (e.g., syringolin A) [12]. In recent years, a plethora of secondary metabolites targeting
the UPP pathway have been isolated from marine sources, particularly from marine sponges and
sponge-associated microbial communities. Among marine invertebrates, soft corals, tunicates, and
sponges are described as an unexhausted source of bioactive NPs. Marine sponges are microbial
fermenters [13], as they are associated with symbiotic microorganisms, which for several sponge
species contribute to 38–57% of the total biomass [14]. The soft coral reef is also a complex holobiont,
resulting from coevolution of multiple macro- and microorganisms [2]. Therefore, these environments
are a compelling arena where each microbial strain had to develop chemical signaling systems
and secondary-metabolite biosynthetic machineries to (a) communicate with the host and other
microbial species [15,16], (b) gain advantage over competitors [17], (c) defend itself or the host against
predators [18], (d) retrieve nutrients from the environment [19].
In this scenario, natural UPP inhibitors from macro- and micro-organisms emerge as chemicals,
which have been optimized during evolution to interact in a selective, potent manner with their
target. As a consequence, NPs still represent an ideal starting point for drug development of novel
UPP inhibitors.
So far, approved drugs targeting human proteasome feature serious side effects together with a
restricted applicability and may even lose their efficacy due to the onset of drug-resistance mechanisms.
Therefore, there is an urgent need to develop novel compounds with enhanced pharmaceutical
properties to overcome these hurdles. In this review, we aim to (a) summarize the role of the UPP in
anticancer therapy and (b) report about recent advances in discovery of natural UPP inhibitors from
marine sources over the last decade, focusing on chemical structures and high-throughput screening
techniques for mining natural UPP inhibitors. Moreover, we will tell about the fascinating story
of the proteasome inhibitor salinosporamide A (marizomib, NPI-0052), providing an example of a
successful drug-development pipeline, from natural product drug-discovery to clinical evaluation,
through sustainable production by microbial fermentation.
2. The Ubiquitin-Proteasome Pathway as a Target for Cancer Therapy
The ubiquitin-proteasome pathway (UPP) is the central protein degradation system in eukaryotic
cells, playing a key role in homeostasis maintenance through proteolysis of regulatory as well as
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misfolded (potentially harmful) proteins. For its function, the UPP intersects many cellular events,
such as cell-cycle, apoptosis, cell survival, and DNA repair [20].
In cancer cells, there is an aberrant production of proteins inducing cell proliferation and/or
inhibiting cell death pathways; these findings laid the fundaments to explore proteasome inhibition as
an anticancer mechanism to shift the fine balance between protein synthesis and degradation towards
cell death [10,21].
Intracellular protein degradation through the UPP involves three main steps (Figure 1):
(a) polyubiquitination of the target protein for proteasome binding; (b) deubiquitylation of the
bounded protein; (c) proteolytic digestion through the proteasome. Protein polyubiquitination
is in charge of the ubiquitin-conjugating system, based upon interaction of ubiquitin-activating
enzyme 1 (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-protein ligase (E3). Deubiquitinating
enzymes (DUBs) detach polyubiquitin tag from the target protein, yielding monomeric ubiquitin (UB)
to enclose a UB recycling circuit. Different cellular signals are generated by UB. Indeed, proteins
are tagged for proteasomal degradation if they are conjugated to a polyubiquitin chain formed by
linking UB molecules through lysine-48 residues. On the other hand, conjugation of a Lys 63-linked
polyubiquitin chain or a single UB molecule to a substrate protein usually affects protein function
and/or localization, regulating diverse cellular processes, such as receptor internalization, endocytosis,
transcription, and DNA repair [22].
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enzymes and the protein is degraded into oligopeptides. Ub, ubiquitin; ATP, adenosine triphosphate; 
ADP, adenosine diphosphate; AMP, adenosine monophosphate; PPi, inorganic pyrophosphate; DUB, 
deubiquitinase. 
The proteasome, commonly referred to as the ‘26S proteasome’, is composed of two subunits: 
(a) the 19S particle, which mediate deubiquitylation in the constitutive proteasome and (b) the 20S 
core particle, responsible for protein degradation into oligopeptides. In the 20S core particle, three 
essential catalytic sites have been identified and termed after enzymes displaying similar functions: 
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E1 uses ATP to adenyl te ubiquitin, yielding a ubiquitin- denylate adduct and pyrophosphate.
Ubiquitin is then transferred from E1 to th ubiquitin-c njugating enzyme E2. The ubiquitin ligas
E3 transfers ubiquitin to a target s bstrate and a polyubiquiti chain is attached to t g the protein for
degradati n by the proteasome complex. Ubiquitin is released by deubiquitinating enzymes a d the
protein is degraded into oligopepti es. Ub, ubiquitin; ATP, adenosine triphosphate; ADP, adenosine
diphosphate; AMP, adenosine monophosphate; PPi, inorganic pyrophosphate; DUB, deubiquitinase.
The proteasome, commonly referred to as the ‘26S proteasome’, is composed of two subunits:
(a) the 19S particle, which ediate deubiquitylation in the constitutive proteasome and (b) the 20S
core particle, responsible for protein degradation into oligopeptides. In the 20S core particle, three
essential catalytic sites have been identified and termed after enzymes displaying similar functions:
the chymotrypsin-like (β5 or ChT-L), trypsin-like (β2), and post-glutamyl peptide hydrolase-like
(caspase-like or β1) activities.
With the FDA approvals (in 2003 and 2005) of the proteasome inhibitor bortezomib for treatment
of relapsed/refractory multiple myeloma and mantle cell lymphoma [23], the UPP has been officially
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validated as a target of great interest for cancer therapy, providing a revolutionary way for treatment
of malignancies.
So far, it is known that proteasome inhibition induces apoptosis in cancer cells via different
concurrent mechanisms (Figure 2). Impairing proteasome activity results in the inhibition of
IkB degradation and, consequently, leads to inactivation of the nuclear factor NF-κB, which is a
tumor-promoting and antiapoptotic transcription factor [24]. Beyond its effect on NF-κB, proteasome
inhibition may (a) prevent degradation of proapoptotic proteins, such as the tumor suppressor protein
p53 and the cell-cycle regulator p27, (b) reduce levels of antiapoptotic proteins (e.g., Bcl-XL, Bcl-2, and
STAT-3), and (c) enhance the c-Jun N-terminal kinase (JNK) pathway, thus promoting a proapoptotic
state [25–27]. Furthermore, decreased levels of proteasome activity generate an imbalance between
proteasome load and its digestion capacity, resulting in accumulation of polyubiquitinated proteins
and reduction of UB recycle [28]. This condition, known as proteasomal stress, has been regarded
as a proapoptotic signal within the cell. In parallel, accumulation of misfolded proteins in the
endoplasmic reticulum and cytoplasm triggers the unfolded protein response (UPR), a stress signaling
pathway which tries to compensate proteasome deficiency, through reduction of protein synthesis and
production of folding chaperones and proteasome components (Figure 2). However, in protracted
stress condition, as during treatment with proteasome inhibitors, UPR cannot guarantee cell survival
and leads to cell cycle arrest and apoptosis [10,29]. Besides the previously described apoptotic effects,
downregulation of proteasome and unprocessed deleterious proteins may also promote aggresome
formation, excessive autophagy and, therefore, cell death (Figure 2) [30].
Mar. Drugs 2018, 16, x 4 of 36 
 
the chymotrypsin-like (β5 or ChT-L), trypsin-like (β2), and post-glutamyl peptide hydrolase-like 
(caspase-like or β1) activities. 
With the FDA approvals (in 2003 and 2005) of the proteasome inhibitor bortezomib for treatment 
of relapsed/refractory multiple myeloma and mantle cell lymphoma [23], the UPP has been officially 
validated as a target of great interest for cancer therapy, providing a revolutionary way for treatment 
of m lign ncies. 
So f r, it is known that proteasome inhibition induces apoptosis in cancer cells via different 
concurrent mechanisms (Figu e 2). I pa ring proteasom  activity results i  the inhib tion of IkB 
degradation and, consequently, leads to in ctivation of the nuclear factor NF-κB, which is a tumor-
promoting and antiapoptotic transcription factor [24]. Beyond its effect on NF-κB, proteasome 
inhibition may (a) prevent degradation of proapoptotic proteins, such as the tumor suppressor 
protein p53 and the cell-cycle regulator p27, (b) reduce levels of anti poptotic p oteins (e.g., Bcl-XL, 
Bcl-2, and STAT-3), and (c) enhance the c-Jun N-terminal kinase (JNK) pathway  thus promoting a 
proapoptotic state [25–27]. Furthermore, decre d levels of protea ome activity generate an 
imbalance between pr t asom  load and its digestion capacity, resul ing in accumulation of 
olyubiquitin ted pro eins and reduction of UB recycle [28]. This condition, known as proteasomal 
stress, has been regarded as a proapoptot c signal ithin the cell. In parallel, accumulation of 
misfolded protein  i  the endoplasmic reticulum and ytop sm trigger  the unfolded protein 
response (UPR), a stress signaling pathway which tries t  compensat  proteasom  deficiency, 
through reduction of protei  synthesis and production of folding haperones a d protea ome 
compone ts (Figure 2). How ver, in protract d stress condition, as during treatment with 
p oteasome nhibitors, UPR c nnot guarantee cell surv val and leads to cell cycle rest and apoptosis 
[10,29]. Besides the p eviously described apoptotic effects, downregulation of pr teasome and 
unprocessed deleterious proteins may als  promot  aggresome formation, excessive autophagy and, 
therefore, cell death (Figure 2) [30]. 
 
Figure 2. Key cellular targets affected by proteasome inhibition. 
In recent years, drug discovery programs in academia and pharmaceutical companies have been 
addressed towards inhibitors of the UPP pathway for cancer treatment. Beyond the proteasome itself, 
enzymes such as E1, E2, E3, and DUBs have emerged as druggable targets for designing new and 
more selective generations of antitumor compounds. 
Figure 2. Key cellular targets affected by proteasome inhibition.
In recent years, drug discovery programs in academia and pharmaceutical companies have been
addressed towards inhibitors of the UPP pathway for cancer treatment. Beyond the proteasome itself,
enzymes such as E1, E2, E3, and DUBs have emerged as druggable targets for designing new and more
selective generations of antitumor compounds.
Blocking the ubiquitination pathway at the level of the ubiquitin-activating enzyme E1 (UBE1)
may potentially impair the great majority of the UB-dependent cellular processes. Knockdown of
UBE1 as well as its chemical inhibition has been associated to decreased levels of ubiquitylated
proteins within cells and to cell death in leukemia rather than normal cells. In addition, inhibition
of this E1 enzyme delayed tumor growth in a mouse model of leukemia [31]. Mechanistically, UBE1
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inhibition induced cell death mainly by prompting endoplasmic reticulum stress and the UPR response
(Figure 2). However, like proteasome inhibition, increased levels of p53 and inhibition of tumor necrosis
factor-α-induced activation of NF-κB have been observed after UBE1 inhibition. In addition to UBE1,
the NEDD8 activating enzyme (NAE) has attracted attention due to its role in regulation of the SCF-E3
ligase activity through neddylation. Blocking NAE-mediated neddylation results in deactivation of
SCF, leading to cell cycle arrest and apoptosis, through the accumulation of p27, NRF2, CDC25A,
HIF1α, and IκB [32].
To date, more than 40 variants of the E2 enzyme have been discovered to be encoded by human
genome. These enzymes are able to regulate the switch from ubiquitin chain initiation to elongation,
the processivity of chain formation and the topology of assembled chains, thereby determining
fate and/or function for the modified proteins. Among members of the E2 enzyme-superfamily,
the ubiquitin-conjugating enzyme Ubc13 forms a complex with Uev1A or MMS2 to ubiquitinate
p53, preventing p53 tetramerization and, consequently, decreasing its transcriptional activity.
Therefore, hampering the formation of Ubc13/Uev1A complexes leads to p53 activation, arresting cell
proliferation and survival (Figure 2). Indeed, knockdown of Ubc13 expression in OCI-Ly10 cells is
accompanied by increased expression of p21 and GADD45, which are known to be p53 targets [33].
More interestingly, it has been reported that overexpression of the ubiquitin-conjugating enzyme E2C
(UBE2C) is a typical feature of a number of cancer cell lines and primary tumors, including lung,
gastric, bladder, and uterine cancers. RNA-silencing of UBE2C, which is involved in ubiquitination
of cell-cycle regulators, caused antiproliferative effects and cell-cycle deregulation in esophageal
adenocarcinoma cells [34].
So far, approximately 600 variants of the E3 enzyme have been identified, each of them being
responsible for binding and ubiquitylating a defined set of substrate proteins. Therefore, it can be
conceived that inhibition of a specific E3 isoform affects a well-defined cellular pathway. The E3
MDM2 (or HDM2) is the main regulator of the p53 tumor suppressor protein degradation process;
as a result, blocking MDM2 activity leads to p53 stabilization and increased anticancer activity of
p53 downstream effectors (Figure 2) [35]. In a similar way, inhibition of the E3 ITCH guarantees
stabilization of p63 and p73, which are known to share several target genes with p53. Furthermore,
it has been reported that several malignancies feature downregulation of the cell-cycle inhibitor p27,
which can be restored through inhibition of its degradation pathway governed by the oncogenic E3
ligase Skp2 (Figure 2) [35].
DUBs are enzymes involved in removal of the UB-degradation signal from proteins, regeneration
of cellular UB pools, and editing of polyubiquitin tag on specific substrates to address their fate.
Among them, UCHs and USPs are the best characterized, with USPs representing more than half of
the known human DUBs. The main function of the variant USP7 is the indirect regulation of p53
homeostasis [36]. USP7 inhibition blocks deubiquitylation of MDM2, which is exposed to intensive
proteasome degradation. Decreased levels of MDM2 stabilize p53, prolonging its beneficial anticancer
effects (Figure 2) [36].
To date, bortezomib, carfilzomib, and ixazomib have received FDA regulatory approval and
have been introduced as proteasome inhibitors in clinical settings. In addition, thalidomide and the
more novel analogues lenalidomide or pomalidomide have been approved for treatment of multiple
myeloma, relying on their selective action against the E3 ubiquitin ligase cereblon [37].
In this contest, natural product drug-discovery has provided a precious contribution to the
search for anticancer lead compounds targeting the UPP pathway. Particularly, exploration of
marine environments is adding novel chemical entities for drug designing, which have been
isolated from either invertebrate (sponges, tunicates, algae, soft corals) or microbial (actinobacteria,
cyanobacteria, fungi) sources. At present, the most interesting story is that of the marine natural
product salinosporamide A (1), which has entered phase III clinical trials, due to its strong biological
activity as irreversible proteasome inhibitor.
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3. Salinosporamide A, a Milestone in Natural Product Drug Discovery
Salinosporamide A (1) as well as several structural analogues (salinosporamides B-K, 2–11) have
been isolated from marine obligate actinomycetes of the genus Salinospora. The salinosporamide family
displays a typical γ-lactam-β-lactone structural moiety; in 1, there are a chloroethyl side chain and a
cyclohexenyl unit at the α positions of the lactam and lactone rings, respectively.
The unique interaction of 1 with all three β catalytic sites of the 20S proteasome was
elucidated through X-ray crystallographic analysis [38]. The molecular mode of action (Figure 3c)
can be summarized in three sequential steps: (1) initially, as it has been reported for other
γ-lactam-β-lactone proteasome inhibitors (e.g., omuralide, Figure 4), the side-chain hydroxy group of
the N-terminal threonine residue (Thr1) of the proteasome cleaves the lactone ring of 1, yielding the
proteasome-inhibitor complex; (2) then, the newly formed tertiary alcohol of 1 displaces the chlorine
atom, leading to the formation of a tetrahydrofuran (THF) ring, by an intramolecular nucleophilic
substitution mechanism; (3) finally, the THF ring prevents hydrolysis of the ester bond between
proteasome and 1 (a) by displacing water molecules and coordinating the α-amino group of Thr1
and (b) by blocking reformation of the β-lactone ring. This unique interaction mode makes 1 an
irreversible inhibitor, tightly bounded to the 20S proteasome. In addition, the cyclohexenyl unit is
essential both to shield the ester bond of the proteasome-inhibitor complex and to establish favorable
hydrophobic interactions in the binding pocket. These interactions are not possible for other known
γ-lactam-β-lactone proteasome inhibitors and therefore could be the reason why 1 is able to recognize
all three β catalytic sites of the 20S proteasome [38].
Salinosporamide A is able to inhibit the proteasome in the low nanomolar range and is the most
active among the members of the salinosporamide family. Natural variants of 1 mainly differ for
modifications at the C-2 side chain, with few exceptions being represented by the decarboxylated
pyrrole analogue salinosporamide C (3), the C-3 ethyl analogue salinosporamide I (9), and the
non-hydroxylated derivative salinosporamide J (10).
Evaluation of biological activity of natural and non-natural salinosporamide variants were
useful to fully understand their mechanism of action and reveal structure-activity relationship (SAR)
features. SAR studies pointed out that the presence of a good leaving group at the C-2 side chain is
essential to exert a strong activity against all the β subunits as it assists the THF ring closure, which
stabilizes the proteasome-inhibitor complex (Figure 3c) [39,40]. Good leaving groups such as halides
(Cl−, Br−, and I−) or sulfonate esters (tosylate, dansylate, mesylate) are well tolerated and can be easily
accommodated in the large S2 binding pocket of the proteasome (Figure S1). Accordingly, non-leaving
groups decrease dramatically drug efficacy. These observations were confirmed by the interesting
case of fluorosalinosporamide (12), which has been prepared by genetic manipulation of the original
organism in B. S. Moore’s laboratory to introduce fluoride instead of chloride as leaving group [41].
The poor leaving group ability of fluoride and the subsequent slow displacement of the F atom during
proteasome-inhibitor interaction is in accordance with the behavior of fluorosalinosporamide as a
partially reversible proteasome inhibitor, thus confirming the mechanism of action discussed above.
As a result, modification of leaving group ability at C-2 allows fine-tuning of proteasome inhibition by
salinosporamides. In addition, it is worthy noting that C-2 stereochemistry of the natural compound
must be retained to keep a strong bioactivity profile as the natural C-2 epimer of 1, salinosporamide
F (6), displayed an about 100-fold weaker activity [39,42].
As regards substitutions of the cyclohexenyl unit at C-5, it has been demonstrated that any C-5
analogue exerted attenuated activity, with exception of the synthetic cyclopentenyl derivative, which
exhibited a bioactivity comparable to 1 (Figure S1) [43]. The minor metabolite antiprotealide (13) from
Salinospora tropica has an isopropyl chain at C-5 and displayed a 50-fold lower inhibitory effect than 1.
Overall, linear substituents at C-5 reduced bioactivity, probably due to the destabilizing ‘waving’ effect
of a more flexible chain in the S1 binding pocket of the proteasome [43].
Further alterations of the natural scaffold of 1, such as the substitution of the methyl group at
C-3 (e.g., salisporamide I (9)) or removal of the hydroxy group at C-5 (e.g., salisporamide J (10)) are
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always associated with a weakened biological effect [40,42]. Taken together, SAR studies showed that
salinosporamide A is the strongest proteasome inhibitor among natural and synthetic members of this
chemical class, thus highlighting a molecule perfectly designed by nature, which placed every single
atom at the right position to optimize interactions with the target [44].
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Besides its established activity as a pan-proteasome inhibitor, 1 has been demonstrated to
(a) enhance apoptosis, suppress osteoclastogenesis, and inhibit invasion through suppression of
the NF-κB pathway [45]; (b) interfere with NF-κB-Snail-RKIP causing downstream inhibition of
antiapoptotic gene products and epithelial to mesenchymal transition [46,47]; (c) induce caspase-8 and
ROS-dependent apoptosis in leukemia cells [48].
Preclinical studies showed the increased efficacy (=increased potency and longer duration
of biological effects) of 1 compared with bortezomib [45]; this observation together with an
attenuated toxicity at therapeutic doses allowed 1 to enter the clinical development process in
2006 with a phase I trial (NCT00396864) in patients with advanced solid tumor malignancies or
refractory lymphoma whose disease had progressed after treatment with standard therapies. Since
then, four additional phase I/II trials were completed to examine safety, pharmacokinetics, and
pharmacodynamics of 1 in patients with (a) relapsed or relapsed/refractory multiple myeloma
(NCT00461045); (b) solid tumors, lymphoma, chronic lymphocytic leukaemia (CLL), Waldenstrom’s
macroglobulinemia, and relapsed and/or refractory (RR) multiple myeloma (NCT00629473);
(c) melanoma, pancreatic carcinoma or non-small cell lung cancer, combining 1 and the HDAC inhibitor
vorinostat (NCT00667082); (d) relapsed and refractory multiple myeloma, combining 1, pomalidomide,
and low-dose dexamethasone (NCT02103335) [49–51]. Furthermore, salinosporamide A was shown
to exert a selective cytotoxic action against malignant glioma stem cells and glioma cell lines with
minimal effect on neural stem cells [52]. Therefore, three clinical studies were recently undertaken and
are still in progress to evaluate (a) a new combination of drugs, 1 and bevacizumab (BEV; Avastin®,
Genentech Inc., South San Francisco, CA, USA), for the treatment of WHO Grade IV malignant
glioma (NCT02330562); (b) the addition of 1 to standard-of-care treatments of radiotherapy (RT),
temozolomide (TMZ), and Optune in patients with newly diagnosed WHO Grade IV malignant
glioma (NCT02903069); (c) efficacy of 1 in newly diagnosed glioblastoma patients (phase III trial,
NCT03345095).
Supply of natural product leads usually hampers their full utilization for clinical development,
as marine natural products are often isolated in trace quantities from original sources. In order to
overcome these hurdles and ensure development of 1, efforts were addressed towards enhanced
production of 1 through optimization of an industrial-scale saline fermentation process, meeting
Current Good Manufacturing Practice (CGMP) guidelines. Indeed, the compound is currently obtained
by cultivation of the natural producer Salinospora tropica, despite more than 10 synthetic strategies have
been developed to produce 1 along years [53]. This is the first example of a GMP saline fermentation
process employed to produce a natural-product drug from a marine microbe, highlighting a feasible
path for drug development from marine natural products.
4. Inhibitors of the Ubiquitin-Proteasome Pathway in the Last Decade (2007–2018)
Marine organisms and microorganisms are able to assemble complex biosynthetic machinery to
produce pharmacologically-active compounds having unusual architectures with no counterparts in
the terrestrial environment. Indeed, natural products from marine sources still represent a source of
inspiration for anticancer drug discovery, where fuelling new ideas is constantly needed.
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inhibitors, yielding the proteasome-inhibitor complex; then, i the case f salinosporamides, the newly
formed tertiary alcohol displaces the chlorine atom, leading to the formation of a tetrahydrofuran ring,
which in turn coordinates the α-amino group of Thr-1. (d) The carbonyl moiety of peptide aldehydes
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(e) Vinyl ketones harbor a Michael system which undergoes 1,4-nucleophilic addition with the Thr1Oγ,
forming a one-step irreversible covalent adduct.
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With the advent of MS and NMR instrumentations for nanoscale structure elucidation [54,55] and
advanced cell- and protein-bioassays, a plethora of secondary metabolites with fascinating chemical
structures and potent cytotoxic properties have emerged from aquatic environments.
Most UPP inhibitors known to date interact specifically with the proteasome. Proteasome
inhibitors usually feature an electrophilic group to allow covalent binding to the proteasome by
nucleophilic attack of the Thr1 hydroxy groups of the proteolytic β subunits (Figures 3 and 4). Based
upon the different chemical nature of the electrophilic site, proteasome inhibitors can be classified in
five groups (Figure 4), including peptide boronates (e.g., bortezomib), peptide aldehydes (e.g., MG132),
macrocyclic vinyketones (e.g., syringolin), β-lactones (e.g., omuralide, salinosporamides), and
epoxyketones (e.g., carfilzomib).
Herein, we aim to review the chemical diversity of natural products from marine sources identified
as UPP inhibitors in the last decade, reporting about not only proteasome, but also E1, E2, E3, and DUBs
inhibitors. We grouped the reviewed compounds according to the canonical structural classification of
natural products.
4.1. Terpenes
A bioassay-guided investigation of the crude extract of the Philippines sponge Acanthodendrilla sp. led
to the isolation of the proteasome inhibitor acanthosulfate (14). Acanthosulfate is a merosesterterpenoid
possessing a scalarane-type carbon skeleton, with an unusual trans-antitrans-syn-anti configuration.
Although showing an IC50 value of 4.5 µM in a proteasome inhibition assay, this compound was found
to be unselective and ineffective in the BMS Oncology Diverse Cell Panel, and therefore any further
development was stopped [56].
An in-depth analysis of the methanolic extract of Rhabdastrella globostellata (South China Sea)
revealed the presence of nine new isomalabaricane-derived natural products, globostelletins A-I
(15–23), together with some known metabolites, such as jaspolides F (24), rhabdastrellic acid A (25),
and stellettin E (26). Isomalabaricanes are a class of sponge-specific trans-syn-trans 6,6,5-tricyclic
triterpenoids. In vitro evaluation of cytotoxicity of 15–26 on a panel of five different cell lines
highlighted selective inhibitory activity against human ovarian carcinoma A2780 cell line, with the
most potent compounds being represented by 25 and 26. Particularly, drug efficacy (a) increased with
the length of the side-chain and the number of conjugated double bounds and (b) was higher for 13-Z
than the 13-E isomers [57]. In this work, Li et al. focused their attention on rhabdastrellic acid A,
observing a similar antiproliferative effect against both A2780 cells and human promyelocytic leukemia
cell line HL-60. Rhabdastrellic acid A was shown to induce apoptosis in HL-60 cells and cell-cycle
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arrest in the G2/M phase through upregulation of p21. This effect is likely related to the proteasome
inhibitory effect of rhabdastrellic acid A, thus blocking the pathway for p21 degradation [57]. Notably,
in a proteasome activity assay, β5 and β2 catalytic sites of the proteasome were equally inhibited by
25, with a rate >80% at a concentration of 30 µM. The UPP pathway could be also damaged by ROS
accumulation, deriving from rhabdastrellic acid A-induction of caspase-3 in HL-60 cells. Surprisingly,
in another study based upon different cell models (hepatic Hep3B and lung A549 cancer cells), 25 did
not cause apoptosis but it was found to induce autophagy-associated cell death through blocking of
Akt pathway [58].
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arrest, autophagy, the MAPK signaling pathway, and the inhibition of the NF-κB-dependent system.
With regards to cell death, 27 was able to induce apoptosis triggering caspases-8- and -9-dependent
pathways. The heteronemin-inhibitory effect of NF-κB may play a key role in inducing a proapoptotic
state within the cells. At a molecular level, it was demonstrated that 27 blocked TNFα-activation of
NF-κB signaling, preventing IkBα degradation and phosphorylation through inhibition of the 26S
proteasome, without affecting IKK activity. All the three proteolytic sites of the proteasome were
inhibited by 27, with IC50 values of 0.4 µM for the chymotrypsin- and trypsin-like catalytic sites, and
>2.8 µM for the caspase-like site.
Petrosaspongiolide M (28) is a marine sesterterpene (Petrosaspongia nigra, New Caledonia) with
a γ-hydroxybutenolide ring, showing a significant ability to inhibit the proteasome activity both
in enzymatic and cell-based assays. Particularly, in cell human-macrophage-derived THP-cell line,
28 inhibited the caspase- and the chymotrypsin-like activity with IC50 values of 0.85 µM and 0.64 µM,
respectively, while the IC50 of the trypsin-like activity was >1 µM [60]. Margarucci et al. identified the
molecular target of 28, applying a chemical proteomic strategy based upon combination of affinity
chromatography and LC/MSMS spectrometry. Briefly, macrophage cell lysates were loaded on a solid
support functionalized with 28, and, after extensive washing, anchored proteins were released and
analyzed by mass spectrometry. In addition, as a consequence of proteasome inhibition, a significant
accumulation of polyubiquitinated proteins could be detected by western blotting after treatment
of THP-1 cells with 28. In an attempt to outline SAR profile of 28, Margarucci et al. evaluated
modulation of proteasome machinery by several natural and synthetic analogues of 28 in vitro and
cell-based bioassays [61]. Overall, minor modifications in the natural analogues—such as acetylation
at C21 and C24 in petrosaspongiolide N (29), acetylation at C25 in acetyl-petrosaspongiolide M (30),
and deacetylation at C24 in petrosaspongiolide P (31)—resulted in weakened bioactivity. Synthetic
analogues of 28 were prepared preserving the γ-hydroxybutenolide ring and replacing the terpene
moiety with a number of aromatic systems. All modifications were ineffective, except for the
benzothiophene ring, which was shown to be a valuable alternative to the terpene moiety only in
enzymatic assays (Figure S2). Indeed, 28 still revealed to be the most bioactive compound in cell-based
assays, suggesting the terpene scaffold to play an essential role in proteasome recognition and/or
molecular adsorption/transport through cell membranes. Notably, the masked aldehyde function at
C25 of 28 is critical for bioactivity and represents a putative reactive site for covalent binding to the
proteasome, as acetylation of C25 lowered dramatically the inhibitory effects in natural and synthetic
analogues. Additionally, a close correlation between accumulation of polyubiquitinated proteins
and the number of apoptotic cells was clearly observed after treatment of human monocytic U937
cells with 28. Afterwards, in-depth investigation of the molecular mechanism of 28 was undertaken,
unveiling its ability to impair complementary pathways involved in protein degradation, namely the
UPP and the autophagy systems [62]. Mass-spectrometry data analysis integrated with molecular
docking studies, highlighted that 28 exerted its proteasome inhibitory activity by binding the active
sites in the inner core of the immunoproteasome and/or covalently binding a Lys residue of the 11S
proteasome activator. The immunoproteasome is a variant of the 26S constitutive proteasome; it is
constitutively expressed in hematopoietic cells and induced in non-immune cells, being involved
mainly in immune response regulation, activation of the NF-κB pathway, and management of oxidative
stress. Upon U937 cells treatment with 1 µM of 28, all components of the immunoproteasome as well
as the 26S ChT-L activity were significantly depressed. Moreover, 28 induced depletion of Beclin-1
intracellular levels and accumulation of LC3II and p62, providing strong evidence for impairment of
the autophagy-mediated proteolysis.
The EtOAc extract of the marine sponge Petrosia corticata (North Sulawesi, Indonesia) revealed a
relevant proteasome inhibitory activity due to the presence of bioactive meroditerpenoids, known as
strongylophorines (32–39) [63]. Chemical purification of this fraction led to the isolation of two novel
strongylophorines (32–33) together with six known analogues. In vitro evaluation of inhibition of the
proteasome ChT-L catalytic site allowed to identify a mixture of strongylophorines-13 and -14 (38) as
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the most potent bioactive compound (IC50 = 2.1 µM). In general, the combination of the hydroquinone
moiety with the hemiacetal functionality in 38 depicted the best pharmacophore within these natural
compounds. Replacement of the hemiacetal function with an acetal (32 and 33) or a lactone group
(34 and 37) resulted in weakened inhibitory effects. At the same time, the hydroquinone-containing
metabolites were more effective than the corresponding dehydrated analogues. Abolishment of the
hemiacetal group with the introduction of a carboxylic acid (35), aldehyde (36), and methyl group (39)
at C-4 was shown to decrease inhibitory activity in this order.
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Sulawesin A (40) and B (41), along with the two known ircinin-1 (42) and -2 (43), were isolated
from a Psammocinia sp. marine sponge (Indonesia) and identified as inhibitors of the ubiquitin-specific
protease 7 (USP7). Structurally, these compounds are furanosesterterpenes with a tetronic-acid moiety.
40–43 were found to be active in vitro in the low micromolar range, with IC50 values of 2.8, 4.6, 2.7,
and 3.5 µM, respectively [64].
Niphateolide A (44) was isolated from the sponge Niphates olemda (Indonesia) as a stereoisomeric
mixture at C-17. The structure of 44 has a diterpene scaffold with a γ-hidroxybutenolide moiety [65].
This compound was found to act as an inhibitor of the HDM2-p53 interaction by ELISA (IC50 = 16 µM).
A family of sequiterpene cyclohexenones, namely epoxyphomalins A–E (45–49), was isolated
from the marine-derived fungus Paraconiothyrium cf sporulosum, obtained from the Caribbean sponge
Ectyplasia perox [66,67]. Dissecting epoxyphomalin chemical structure, it can be deduced these
compounds are made of a polyketide-derived epoxydon moiety and an isoprenoid-derived decalin
ring. The cytotoxicity of compounds 45–49 was investigated using a monolayer cell survival and
proliferation assay in a panel of 36 human cancer cells, with 45 exerting the highest cytotoxic effect in
the low nanomolar range (i.e., IC50 value of 26 nM against breast cancer MAXF 401NL). As 47 and
49 lacked a significant cytotoxic action, it could be argued that modifications at C-1 are crucial for
bioactivity. Hydroxymethyl and methyl substituents allowed to keep cytotoxicity while the carboxylic
group abolished any effect. Furthermore, the potential antitumor activity of 45 and 46 was related
to proteasome inhibition, as suggested by in vitro enzymatic-assays and the COMPARE analysis of
the cytotoxic selectivity pattern of 46. While the cytotoxic selectivity profile of 45 did not show any
correlation with standard antitumor compounds, 46 exhibited the same selectivity pattern as the
proteasome inhibitor tyropeptin A [66]. Interestingly, 45 exerted a similar extent of inhibition against
all the three proteolytic sites of the 20S proteasome, whereas 46 was able to inhibit preferentially the
chymotrypsin-like activity in enzymatic assays [67].
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Using an EGFP-UL76 high-content screening assay, Ling and colleagues screened marine natural
products from Formosan soft corals of the genus Sarcophyton, leading to the identification of four
UPP inhibitors—namely sarcophytonin A (50), sarcophytoxide (51), sarcophine (52), and laevigatol
A (53) [68]. Chemically, these compounds are monocyclic diterpenes displaying a cembrane-based
scaffold. Compounds 50–53 exhibited a similar behavior as bortezo ib and MG132, eliciting increase
of EGFP-UL76 aggresome formation, due to impairment of proteasome degradation activity. These
cellular effects were flanked by accumulation of polyubiquitylate proteins for compou ds 50–52.
Notably, compounds 50 and 52 were shown to deregulate ubiquitylation of the pro easomal 19S S5a
subunit i a different way from bortezomib, suggesting a distinct mechanism of action involved in
UPP inhibition for the soft-coral derived compounds [68].
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4.2. Alkaloids
Aaptamines are a group of benzo[de][1,6]-naphthyridine alkaloids commonly found in marine
sponges of the genus Aaptos, displaying anticancer properties among other bioactivities. Tsukamoto
et al. demonstrated the ability of aaptamine (54), isoaaptamine (55), and demethylaaptamine (56) to
inhibit the chymotrypsin-like and caspase-like activities of the proteasome (with IC50 values ranging
from 1.6 µg/mL to 4.6 µg/mL), while showing less inhibition of the trypsin-like activity of the
proteasome [69]. 54–56 were able to exert a cytostastic/cytotoxic effect against HeLa cells, even if
this action did not correlate with their efficacy in proteasome inhibition, thus suggesting concurrent
mechanisms were involved in their mode of action. It has been observed 54 induces a p21-dependent
G2/M cell-cycle arrest, where increased p21 expression could be related to proteasome inhibition.
In a subsequent study, aaptamines were shown to exert similar anticancer effects in cisplatin-sensitive
and -resistant human embryonal carcinoma cell lines NT-2 [70]. Despite 54, 55, and 56 promoted
different alterations in protein expression, gene ontology analyses identified myc, p53, and TNF as
putative targets or downstream effectors of aaptamines in NT-2 resistant cells. Further investigations
about the mechanism of action of 54–56 enabled detection of (a) enhanced levels of AP-1 and NF-κB
transcriptional activities and (b) unaffected (for 54) or downregulated (for 55 and 56) p53 transcriptional
activity upon treatment with aaptamines at high nontoxic concentrations [71]. Interestingly, at low
nontoxic concentrations, a significant inhibition of EGF-induced JB6 cell transformation could be
appreciated, unveiling cancer preventive properties for 54–56 [71]. Recently, in vitro and in vivo assays
shed light on a dual-induction of p21 and p27 by aaptamine alkaloids, responsible for G0/G1 cell cycle
arrest and apoptosis specifically in t(4;11) leukemia cells [72].
The tetrahydroisoquinoline-alkaloid salsolinol (57) was isolated from the Indonesian sponge
Xestospongia cf. vansoesti together with three analogues—namely norsalsolinol (58), cis-4-hydroxysalsolinol
(59), and trans-4-hydroxysalsolinol (60)—in the frame of a research program aiming to discover novel
lead compounds as proteasome inhibitors [73]. Compounds 57 and 58 impaired the chymotrypsin-like
activity of the 20S proteasome preparation from human erythrocytes, with IC50 values of 50 µg/mL
and 32 µg/mL, respectively, while 59 and 60 were inactive. For 57 and 58, this biological effect was
flanked by cytotoxicity against human cervix epithelioid carcinoma HeLa cells at high micromolar levels.
Furthermore, 57 exerted cytotoxic action against murine leukemia (L1210), human amnion (FL), human
oral epidermoid carcinoma (KB), and human lung adenocarcinoma (A549) cell lines. Interestingly, 57 was
previously detected in mammalian brains where it has been recognized to act as a neuromodulator [74];
nonetheless, this compound is neurotoxic and is involved in the etiopathogenesis of Parkinson’s disease at
non-physiological concentrations, probably due to its ability to induce dopaminergic neuron death through
inhibition of the proteasome.
Hyrtioreticulins A (61) and B (62) were obtained after purification of the organic extract from
the Indonesian sponge Hyrtios reticulatus. Compounds 61 and 62 are epimeric tetraydro-β-carboline
alkaloids exhibiting ubiquitin-activating enzyme (E1) inhibition with IC50 values of 2.4 µM and 35 µM,
respectively [75]. After binding ATP and ubiquitin in the relevant binding sites, E1 enzymes catalyze
adenylation of ubiquitin, which is subsequently transferred to a cysteine-residue in the active site of E1
through formation of a thioester bond. Mechanistically, hyrtioreticulins have been shown to interfere
with E1 activity after ubiquitin has been accommodated in its binding site, differently from himeic acid,
which hampers ubiquitin recognition by E1 [76]. The trans configuration at C-1 improves E1 inhibition
of 61 compared to 62, while the absence of the imidazole ring (as observed in hyrtioreticulin E, which
displays a methyl group instead of the imidazole) results in the loss of bioactivity [75]. Although
being a highly potent E1-inhibitor in enzymatic assay, it is worth mentioning that 61 displayed weak
cytotoxicity against HeLa cells.
Evaluation of proteasome inhibitory activity of three spongean oroidin-derived alkaloids was
the object of the work of Lansdell and colleagues. These molecules—namely palau’amine (63),
dibromophakellin (64), and dibromophakellstatin (65)—were found to inhibit the chymotrypsin-
and caspase-like activities of the 26S proteasome as well as the chymotrypsin-like activity of the
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immunoproteasome, in the low micromolar range (2.3–27.1 µM), while lacking any relevant effect
against the trypsin-like proteolytic site [77]. This behavior may at least partly explain the cytotoxic
properties of these compounds. The natural (−)-enantiomer of 63 was the most bioactive compound
and binding of 63 to the 20S proteasome was consistent with an irreversible inhibitory mechanism,
according to kinetics data and washing experiments. Deeper investigations revealed that 63 induced
ubiquitinylated proteins accumulation and prevented IkBα degradation in HeLa cells, through negative
modulation of the proteasome [77].
Spongiacidin C (66), hymenialdisine (67), and debromohymenialdisine (68) are pyrrole alkaloids
derived from the Indonesian sponge Stylissa massa [78]. Although being closely related from a structural
point of view, only 66 exhibited a significant and rather selective inhibition of the deubiquitylating
enzyme USP7 (IC50 = 3.8 µM) in a panel of five different USP family members (USP7, USP2, USP8,
USP21, and SENP1). The hydantoin ring in 66 is essential for bioactivity, as replacing it with an
aminoimidazolinone ring weakened dramatically inhibitory properties of 67 and 68. In follow-up
cytotoxic assays, compound 66 was unable to affect proliferation of the p53 wild type, USP7 expressing
human colorectal cancer cell line HCT-116 even at 50 µM concentration [78].
Manzamines are a large family of complex polycyclic alkaloids, possessing a fused and bridged
tetra- or pentacyclic ring system, which is usually attached to a β-carboline moiety. Recently, purification
of the chemical extract of Acanthostrongylophora ingens (Indonesia) afforded two further members of the
manzamine family, acantholactam (69) and pre-neo-kauluamine (70), along with manzamine A (71) and
neo-kauluamine (72) [79]. Acantholactam displays an hexenoic-acid moiety linked to the γ-lactam ring,
probably derived from oxidative cleavage of the hexahydroazocine ring of 71; neo-kauluamine is likely a
dimerization-product of 70. Among these compounds, 72 was found to act as the most potent inhibitor of
the chymotrypsin-like activity of the 20S proteasome particle (IC50 = 0.13 µM) and as the most effective
cytotoxic agent against HeLa cells (IC50 = 5.4 µM). A certain degree of these biological effects was also
detected with compounds 70 and 71, but bioactivity was dramatically lowered in assays based upon
treatment with 69, thus revealing that the hexahydroazocine ring is an essential part of the pharmacophore
of these molecules.
Further investigations of the metabolome of Acanthostrongylophora ingens expanded the manzamine
family, yielding four new proteasome inhibitors (73–76) [80]. Acanthomanzamines A (73) and B (74)
were identified as the first manzamine-related alkaloids where the β-carboline moiety is replaced by a
tetrahydroisoquinoline ring, while acanthomanzamines D (75) and E (76) possess an additional oxazolidine
and 2-methyloxazolidine ring, respectively, fused to the canonical manzamine backbone. SAR observations
revealed two clear bioactivity trends: (1) tetrahydroisoquinoline-acanthomanzamines were more cytotoxic
than the β-carboline derivatives against HeLa cells; (2) on the other hand, the latter compounds were
more effective as inhibitors of the chymotrypsin-like proteolytic site. Overall, enzymatic assays with
manzamine-alkaloids 69–76 highlighted that combination of an intact hexahydroazocine ring and a
β-carboline moiety enhanced proteasome inhibitory activity of manzamines.
Two β-carboline alkaloids, variabines A and B (77–78), were isolated from the Indonesian sponge
Luffariella variabilis and evaluated in enzymatic assays for their ability to target the UPP pathways
as modulators of E1, E2, E3, and chymotrypsin-like activities. Interestingly, it was reported that 78
repressed both the chymotrypsin-like activity of the proteasome and the Ubc13–Uev1A interaction,
with IC50 values of 16 and 20 µM, respectively [81]. E1 and E3 activities were unaffected after treatment
with 77 and 78. In addition, sulfonation of the hydroxy-group at C6 in 77 lowered significantly E2-
and proteasome-inhibitory activities.
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Clement et al. developed a high-throughput electrochemoluminescent screening method to detect
the ubiquitin-ligase activity of the E3 enzyme HDM2 in natural product extracts. Using this method,
bioassay-guided fractionation of the organic extract of the ascidian Lissoclinum cf. badium (Papua
New Guinea) afforded a benzopentathiepin alkaloid, isolissoclinotoxin B (79), and two pyridoacridine
alkaloids—diplamine B (80) and lissoclinidine B (81)—displaying HDM2-inhibitory activities with
IC50 values of 58.6, 101.3, and 98.1 µM, respectively [82]. Although being toxic to retinal pigment
epithelial (RPE) cells, compou d 79 did not s ow the expected increase of p53 lev ls, which usually
occurs after HDM2-inhi ition. On the oth r hand, compound 80 und rwent degradation easily over
time in cell-based as ays. Therefore, lissoclinidine B was selected for further inves igation. Notably, 81
increased p53 and HDM2 levels more efficiently in cell-based assays than in nzymatic assays, unveiling
that other mechanisms than the E3-inhibitory activit were involved in its action. Indeed, the highest
E3-inhibitory activity was already observed at 10 µM of 81 [82]. Within the HDM2 pathway, it was
demonstrated that 81 increased cellular levels of HDM2 and p53 through inhibition of HDM2-mediated
ubiquitylation of HDM2 and p53, thus preventing their proteasome-degradation. More interestingly,
this compound selectively killed transformed cell lines harboring wild-type p53, triggering apoptosis
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in a p53-dependent manner. Using mouse embryo fibroblasts (MEFs) and HCT116 as cell models,
a marked decrease of wild-type p53 cell viability was detected at 20 µM while p53-deficient cells were
resistant to drug-treatment [82].
An extensive analysis of the ethanolic extract from the green alga Cladophora fascicularis (China)
allowed to identify six phaeophytins (82–87), that can be classified as alkaloids possessing a
porphine skeleton and a long chain diterpene alcohol, namely phytol [83]. These compounds
were determined as porphyrinolactone (82), 20-chlorinated (132-S)-hydroxyphaeophytin A (83),
(132-S)-hydroxyphaeophytin B (84) and A (86), and (132-R)-hydroxyphaeophytin B (85) and A (87).
All the previous phaeophytins were shown to inhibit TNFα-activated nuclear translocation of NF-κB
in HeLa cells at 50 µM, with 85 and 87 being the most potent among the tested compounds [84].
In addition, compounds were tested in vitro to provide a first evidence for the potential relationship
between the inhibitory effect of NF-κB activation and proteasome inhibition. In enzymatic assays,
phaeophytins revealed to inhibit the ChT-L activity of the 20S proteasome. Particularly, preliminary
SAR emerged from these assays: (a) the phaeophytin-B-type molecules were stronger proteasome
inhibitors than the phaeophytin-A-type compounds, suggesting a key role of the aldehyde group
at C7 in drug–target interaction; (b) 132-R epimeric phaeophytins exerted a stronger effect than
132-S epimeric phaeophytins; (c) chlorination at C20 improved inhibitory activity of 83 compared to
86 [84]. It is worthy to mention that a positive correlation between NF-κB deactivation and proteasome
inhibition was observed only in the case of 85.
4.3. Peptides
The cyclic peptide scytonemide A (88) was isolated through bioassay-guided fractionation of the
extract from the cultured freshwater cyanobacterium Scytonema hofmannii [85]. The core structure of
this peptide contains an unusual imine bond, which could represent an electrophilic site for covalent
binding with the side-chain hydroxy group of the N-terminal threonine residue of the proteasome.
Although being a potent 20S proteasome inhibitor (IC50 = 96 nM vs. the ChT-L proteolytic activity)
in enzymatic assays, 88 lacked antiproliferative effects against human colon cancer HT-29 cell line.
It was demonstrated that 88 penetrated cell membrane and inhibited 20S proteasome activity in a
luminescence-based cellular assay, displaying an 80% inhibition rate at 6.7 µM, a concentration where
no cytotoxicity was observed. Chemical instability or early metabolic degradation of 88 could explain
the failure of this compound in exhibiting a cytotoxic effect [85].
The cyclic depsipeptide largazole (89) was isolated from tropical marine cyanobacteria of the
Symploca genus. Compound 89 contains a methylthiazoline-thiazole moiety in the peptidic core and a
rare 3-hydroxy-7-mercaptohept-4-enoic acid unit, which is linked to an octanoate residue through a
thioester bond. Largazole possesses highly differential antiproliferative activity at nanomolar levels,
preferentially targeting transformed over non-transformed cells [86]. Beyond acting as an inhibitor
of class I histone deacetylases [86], 89 was reported to inhibit the ubiquitin-activating enzyme E1
(IC50 = 29 µM) [87]. Particularly, 89 blocked the adenylation step of E1 activation in a nucleotide
exchange assay. Furthermore, it was shown to reduce ubiquitylation of p21 and TRF1 in vitro, leading
to their stabilization within cells. In addition, E1 inhibition was demonstrated to be not related to the
histone deacetylase-inhibitory effect of 89. Largazole appeared to be specific for the human ubiquitin
pathway as it was relatively inactive towards the ubiquitin-like protein SUMO1 and the enzyme
Uba1p, a homolog of E1 in Schizosaccharomyces pombe. Development of largazole analogues (Figure S3)
unveiled that the intact macrocyclic peptidic core as well the presence of the hydrophobic side chain
are crucial for the inhibition of the ubiquitin-activating enzyme E1, while the thioester bond is not
essential [87].
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Two novel α,β-epoxyketone proteasome inhibitors, namely carmaphycin A (90) and B (91), were
found in trace amounts through NMR- and bioassay-guided purification of the extract from the marine
cyanobacterium Symploca sp. [88]. Carmaphycin A displays a leucine-derived epoxyketone warhead
linked to a methionine sulfoxide residue, in turn connected to a N-hexanoyl-valine unit. On the
other hand, the sulfoxide group of 90 was replaced by a sulfone in 91. Both compounds acted as
irreversible proteasome inhibitors of the 20S proteasome from Saccharomyces cerevisiae, at nanomolar
levels (IC50 = 2.5 nM). Notably, carmaphycins exerted potent antiproliferative effects against lung,
colon, and brain cell lines in the low nanomolar range (1–50nM), with the most sensitive cell lines
exhibiting mutations of KRAS and tp53 genes. Differently from other proteasome inhibitors, 90 and
91 were significantly more effective against solid tumor rather than leukemia cell lines. Through
combination of molecular modelling and crystallographic studies, a comprehensive understanding of
the proteasome-binding mode of carmaphycins was achieved [89]. The lipopeptidic core is involved in
key interactions to form a stable anti-parallel beta sheet within the ChT-L binding site and positions
correctly the epoxyketone warhead for covalent binding of the Thr1 proteasome catalytic residue.
The inhibition process consists of a two-step mechanism (Figure 3a). Initially a 1,2-addition of the
γ-OH group of Thr1 to the carbonyl group of the epoxyketone leads to the formation of a reversible
hemiketal derivative; then, the α-amino-group of Thr1 makes a nucleophilic attack at C-2 of the
epoxide moiety to give a stable morpholine adduct [89].
Fellutamides A–F (92–97) are lipopeptide aldehyde inhibitors of the human proteasome and
come from different fungi, including some marine species (Penicillium fellutanum, Aspergillus versicolor).
Chemical structures of fellutamides (classified according to Pirrung et al.) mainly differ for the length
of the N-terminal fatty-acyl chain and the side chain group of the C-terminal amino acid residue [90].
Fellutamides were described as highly cytotoxic compounds in the literature. Fellutamide B (93) was
reported to have antiproliferative activity against sarcoma, glioblastoma, fibroblast, glioma, leukemia,
epidermoid carcinoma, and pheochromocytoma cell lines through induction of cell-cycle arrest [91].
In addition, fellutamides D (95) and E (96) were reported to be inactive against A549 lung carcinoma
cells, but to inhibit PC3 prostate cancer cell-growth by inducing G2/M phase arrest and apoptosis [92].
Human skin cancer cells (SK-MEL-2), CNS cancer cells (XF498), and colon cancer cells (HCT15) were
very sensitive to treatment with fellutamide F (97), which was as potent as doxorubicin against these
cell lines [93]. In enzymatic assays, 93 inhibited the chymotrypsin-, caspase-, and trypsin-like activities
of the human proteasome with IC50 values of 9.4 nM, 1.2 µM, 2 µM, respectively [91]. A significant
downregulation of the ChT-L proteolytic capacity was also observed for 95 and 96 [92]. The crystal
structure of the yeast 20S proteasome in complex with fellutamide B provided insights into the
inhibitory mechanism of 93 [91,94]. The aldehyde group of 93 undergoes nucleophilic attack by the
γ-OH group of Thr1 of the proteasome, thus yielding a hemiacetal adduct, which in turn forms
a stabilizing hydrogen bond with the free amino group of Thr1 (Figure 3d). Further interactions
of the peptidic core of 93 are engaged to stabilize the inhibitor-proteasome complex [91]. Notably,
the long hydrophobic tail of 93 was found to assume different orientations according to the proteolytic
site, while the peptidic skeleton adopts very similar conformations in all the three catalytic sites.
Interestingly, only in the ChT-L proteolytic site, the C24–C29 fragment of the fatty acyl chain is
accommodated in a hydrophobic groove of the proteasome, which is formed during ligand binding,
thus highlighting a certain degree of plasticity of the proteasome [91]. Kinetic studies unveiled that 93
followed a reversible two-step slow binding mechanism for proteasome inhibition [94].
Mar. Drugs 2018, 16, 467 21 of 37
Mar. Drugs 2018, 16, x 21 of 36 
 
 
4.4. Sphingolipids and Phospholipids 
Leucettamol A (98) is an α-ω bifunctionalized sphingolipid found in the Indonesian sponge 
Leucetta microrhaphis. This compound was identified as the first inhibitor of the formation of the 
heterodimer complex between the ubiquitin-conjugating enzyme Ubc13 and Uev1A in ELISA assay, 
with an IC50 value of 106 µM [95]. Interestingly, leucettamol was unable to inhibit formation of the 
Ubc13/MMS2 complex, although Uev1A and MMS2 share approximately 90% amino acid sequence 
identity. These results suggested a selective E2-inhibitory action of 98. In addition, preparation and 
bioevaluation of a fully reduced (99) and a tetraacetate (100) derivatives of leucettamol allowed to 
achieve some clues about SAR [95]. Hydrogenation of 98 improved bioactivity as 99 had a 12-fold 
higher potency; on the other hand, fully acetylation of 98 yielded a completely inactive compound 
(100), unveiling that free hydroxy and/or amino groups are crucial for drug–target interactions. 
4.4. Sphingolipids and Phospholipids
Leucettamol A (98) is an α-ω bifunctionalized sphingolipid found in the Indonesian sponge
Leucetta microrhaphis. This compound was identified as the first inhibitor of the formation of the
heterodimer complex between the ubiquitin-conjugating enzyme Ubc13 and Uev1A in ELISA assay,
with an IC50 value of 106 µM [95]. Interestingly, leucettamol was unable to inhibit formation of the
Ubc13/MMS2 complex, although Uev1A and MMS2 share approximately 90% amino acid sequence
identity. These results suggested a selective E2-inhibitory action of 98. In addition, preparation and
bioevaluation of a fully reduced (99) and a tetraacetate (100) derivatives of leucettamol allowed to
achieve some clues about SAR [95]. Hydrogenation of 98 improved bioactivity as 99 had a 12-fold
higher potency; on the other hand, fully acetylation of 98 yielded a completely inactive compound (100),
unveiling that free hydroxy and/or amino groups are crucial for drug–target interactions.
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4.5. Sterols
Following discovery of 98, two further compounds (113–114) inhibiting formation of the
Ubc13/Uev1A were isolated from the sponge Lissodendryx fibrosa (Indonesia). Manadosterol A (113)
and B (114) are two sulfonated dimeric sterols, exhibiting higher activity than leucettamol, with IC50
values of 0.09 µM and 0.13 µM, respectively [97].
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Plasma cells are undoubtfully the most sensitive cell type to downregulation of the UPP, as they
have to sustain high rates of immunoglobulin synthesis. This is even more true for blood cancer
cells, which are characterized by an aberrant production of proteins. The increased protein synthesis
dramatically affects the fine balance between proteasome load and capacity, making malignant plasma
cells more sensitive to proteasome inhibition than normal cells [102]. This selective action can be also
explained considering that the NF-κB pathway is constitutively activated in myeloma cells and the
enhanced IkB-mediated inhibition of NF-κB is one of the main downstream effects of proteasome
inhibition [103]. In addition, myeloma cells are more sensitive to proteasome inhibition as they
accumulate higher amounts of misfolded proteins, leading to a proteotoxic state which promotes
apoptosis and UPR response [104].
To date, several preclinical studies were addressed to elucidate acquired and inherent resistance
mechanisms to proteasome inhibition, most of these studies being based upon treatment with
bortezomib. Overall, cell responses hampering proteasome inhibition are directed either to improve
proteasome capacity or reduce proteasome load, thereby promoting cancer cell survival.
In vitro assays revealed resistant cell lines developed mutations in the binding pocket of
the subunit β5 of the 20S proteasome, which could negatively affect the reversible binding of
bortezomib [105]. However, such mutations were not detected in bortezomib-resistant patients [10].
Induction of expression of proteasome subunits β5, β2, and β1 was observed in myeloma cell lines
trying to compensate proteasome inhibition, even if this adaptive response was too weak to fully
explain the acquired resistance by treated cells [106]. The antioxidant response pathway was reported to
be activated in resistant cells, leading to induction of the proteasome maturation protein (POMP), which
is essential to assemble proteasome subunits, and, therefore, improve its degradation capacity [107].
Furthermore, the proteasome-inhibitor-resistant phenotype was shown to enhance also the EGFR
signaling cascade to increase production of proteasome subunits [108].
Impairing proteasome activity induced also expression of heat-shock proteins and chaperones
to improve protein folding, reduce proteotoxic stress, and restore proteasome load/capacity ratio,
thereby raising the apoptosis threshold [109]. Similarly, proteasome inhibition forced cells to
activate alternative proteolytic processes, such as the aggresome-autophagy pathway, to reduce the
‘proteasomal stress’, sequester deleterious proteins in aggresomes, and guarantee cell survival [110].
Notably, Leung-Hagesteijn et al. discovered that myeloma cells with low expression levels of IRE1 and
XBP-1 displayed less differentiation, decreased immunoglobulin synthesis, lower proteasomal stress
and innate resistance to bortezomib, compared to other tumor subpopulations which were sensitive
to bortezomib [111]. In bortezomib-resistant myeloma cell models, induction of IGF-dependent AKT
signaling promoted an antiapoptotic state within cells. Cotreatment with bortezomib and an IGF1R
inhibitor resulted in re-sensitization of these cancer cells to bortezomib and increased cell death [112].
Clinical studies revealed bortezomib to be ineffective in treatment of solid tumors. A first
hypothesis to explain this resistance was based upon (1) insufficient tumor penetration, related
to tumor architecture and/or limited perfusion; and (2) pharmacokinetic and pharmacodynamic
properties of this drug, which appears to be distributed mainly to blood and bone marrow rather than
other tissues [10,100,113]. Moreover, key proteasome target proteins in solid tumors are likely to be
different from those in hematological malignancies due to dependence on distinct oncogenic signaling
pathways and the hypoxia-induced accumulation of oncoproteins [51]. As the three catalytic sites
of the proteasome have different substrate selectivity, a broader and stronger proteasome inhibition
rather than the reversible β5-specific inhibition of bortezomib could be necessary for treating solid
tumors. In 2017, Weyburne and colleagues demonstrated that triple-negative breast cancer cell lines
survived after exposure to doses of bortezomib or carfilzomib, which were able to block exclusively
the β5 subunit of the proteasome [114]. Using the CRISPR gene editing, Weyburne et al. switched off
the β2 and β1 proteolytic functions of the proteasome to show that ablation of the β2 activity was
enough to re-sensitize breast cancer cells to bortezomib and carfilzomib. These data were confirmed
by chemical inhibition of the β2 catalytic site [114]. It can be deduced that residual proteolytic
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β2-activity contributes significantly to cell survival in solid tumors after blockade of the β5 subunit,
thus accounting for the observed intrinsic resistance.
The adaptive hyperactivation of β2 and β1 proteolytic functions was also observed after treatment
of multiple myeloma and solid tumor patients with salinosporamide A, even if this drug can
recognize all three β catalytic sites of the 20S proteasome. This compensatory response occurred after
β5-inhibition upon initial dosing with salinosporamide A and was related to an allosteric interaction
between the different proteasome subunits rather than overexpression of new proteasomes, as expected
for an irreversible inhibitor [51]. However, differently from bortezomib, Levin et al. demonstrated
that repeated dosing with salinosporamide A overcame the initial compensatory upregulation of β2
and β1 activities, thus resulting in a robust pan-proteasome inhibition due to the broader spectrum
of the molecule [51]. Therefore, the irreversible mode of action of 1 as well as its ability to block all
three β catalytic sites of the 20S proteasome suggest a novel approach to achieve efficacy against solid
tumors too.
6. High-Throughput Screening for Discovery of Natural UPP Inhibitors
Differently from combinatorial chemistry products, natural products often feature complex
structural architectures covering a more diverse chemical space and, therefore, represent a valuable
treasure to discover novel biological activities. However, the whole purification process and sustainable
production of bioactive natural compounds imply a time-consuming and often non-straightforward
workflow. Different high-throughput screening (HTS) approaches have been developed to accelerate
target-oriented fractionation of organic extracts leading to successful drug discovery. Herein,
we summarize HTS methods specifically addressed to isolation of natural UPP inhibitors from
heterogenous and complex extracts.
6.1. HTS Methods for Detection of Natural Proteasome Inhibitors
UV–vis spectrophotometric determination of proteasome activity is the most applied HTS for
discovery of UPS-targeting molecules from crude extracts of natural sources. These assays are
based upon non-natural peptides, featuring a C-terminal chromophore group, which generates
a fluorescence signal after proteasomal-hydrolysis. The peptide sequence is designed to exhibit
selective affinity for a specific proteasome subunit and, therefore, measure proteolytic activity of each
catalytic site. The most commonly used chromophores are aromatic groups, including 2-naphtylamine,
7-amino-4-methyl-coumarin, and 4-methoxy-2-naphtylamine. This methodology is suitable for
enzymatic- and cell- based assays and the fluorescence signal is directly proportional to the digestion
capacity of the proteasome, allowing a fast, quantitative assessment of bioactivity [115]. In 2011,
Götze and Saborowski described the application of NanoDrop fluorometry for measuring proteasomal
enzymatic activities using fluorogenic substrates [116]. The main advantage of NanoDrop devices can
be found in the reduction of amount of sample extracts, substrates, and cofactors to be used for an
enzyme assay. However, UV–vis techniques are prone to a plenitude of artifacts caused by quenching
and/or autofluorescence, which are quite common interferences when heterogeneous and colorful
organic extracts are analyzed. In addition, a limiting factor with fluorescent substrates is that small
adducts mimicking natural substrates and non-natural peptides may not be hydrolyzed efficiently.
An alternative HTS method relies on the use of a fluorescent-labeled proteasome inhibitor
(fluorescent probe), which has to bind irreversibly all the three catalytic sites of the proteasome [115].
Aliquots of complex organic extracts are added to the assay mixture, including intact cells, cell-lysates,
or purified proteasome. After incubation, the selected irreversible probe is added to the mixture
and if the sample contains an inhibitory compound, the active sites of the proteasome are already
blocked, thereby hampering labeling of the proteasome. Suppression of the fluorescence signal is
indicative of proteasome inhibition and can be easily quantified. The fluorescence signals can be
detected (a) through SDS-PAGE and fluorescence gel scanning devices for purified proteasomes and
cell lysates, or (b) through confocal microscopy or flowcytometry if intact cells are used in the assay.
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This method excludes generation of false positives, as potential interfering compounds are removed
through SDS-PAGE. However, this technique does not allow detection of reversible, non-covalent
inhibitors of the proteasome as they are displaced by the competitive binding of the probe.
Recently, Stein et al. developed an NMR-based proteasome assay to detect inhibitory compounds
in conglomerates [117]. This screening method uses a purified 20S core particle and a natural peptide
substrate, which is selectively labeled through introduction of a carbonyl 13C probe at the scissile
amidic bond. Proteolytic activity of the proteasome can be qualitatively and quantitatively evaluated
by a peak shift in the 13C-NMR spectrum from 173 ppm to 177 ppm, corresponding to the intact amide
educt and the hydrolyzed carboxylic acid derivative, respectively. NMR spectroscopy is suitable for
analysis of crude mixtures as it is not affected by diffraction, autofluorescence or quenching as for
UV–vis techniques. Moreover, the signal-to-noise ratio is considerably increased. In the carbonyl
resonance area of the NMR spectra, putative overlapping NMR signals due to other compounds in the
sample extract can be overlooked as natural compounds display only 1.1% of 13C carbon compared
to the 13C-enriched probe used for the assay. The NMR-based approach allows screenings of almost
100 samples per day, as the recording time to acquire a single spectrum is about 15 min.
6.2. HTS Methods for Detection of Natural Inhibitors Targeting E1, E2, E3, and DUBs Enzymes
The ubiquitination cascade starts with the ATP-dependent loading of the E1-ubiquitin activating
enzyme. E1 enzymes use ATP to adenylate the C-terminus of ubiquitin, yielding a ubiquitin-adenylate
adduct and pyrophosphate. Then, an active site cysteine within E1 cleaves the ubiquitin-AMP ester
bond, forming an E1-Ub intermediate through a thioester bond between the C-terminus of UB and
the sulfhydryl of cysteine. Ub is transferred from the E1 to another active site cysteine within the
E2-ubiquitin conjugating enzyme. The E3 ligase binds to both the E2 and the substrate, leading to
isopeptide bond formation between Ub and a lysine residue of the protein substrate.
The most widely applied method to measure E1 activity is monitoring the formation of E1-Ub
intermediate by semi-quantitative Western blotting analysis. Generally, epitopes (e.g., FLAG) or
fluorescent-tags are attached to E1 enzymes or ubiquitin to have accurate quantification and increase
sensitivity [75,87]. This technique can be easily adapted for evaluation of ubiquitin-E2 thioester bond
formation, using an assay mixture including an ATP- and Ub-pre-charged E1 enzyme and a specific
purified E2 protein [87]. However, western blotting analyses are time-consuming assays and high
variability in signal detection may occur between different experiments.
With regard to evaluation of E2-ubiquitin conjugating activity, a 96-well ELISA assay has been
set up to evaluate inhibition of the Ubc13-Uev1A (or MMS2) interaction, using human-Ubc13-coated
multiwell plates and FLAG-Uev1A (or MMS2) [95]. Similarly, the ELISA method has been applied to
monitor interaction between the transcription factor p53 and the E3 ligase HDM2, using the human
p53 to coat the 96-well plates, the native HDM2 and a commercially available anti-HDM2 antibody for
quantitative assessment of inhibitory activity [96].
In 2008, Sasiela and colleagues developed a high-throughput electrochemiluminescent assay to
discover HDM2 inhibitory compounds from natural product extracts [118]. This system estimates E3-ligase
activity of HDM2 measuring its autoubiquitylation capacity. Particularly, the HDM2 assay is based upon
detection of polyubiquitylated Hdm2 by electrochemiluminescence generated by a ruthenium labeled
polyubiquitin antibody. Assay samples, ubiquitin, and a pre-charged E1/E2 solution are added to the
multiwell-plates containing Hdm2, and, after 30 min, the ruthenium-labeled polyubiquitin antibody is
added too to record luminescence by a plate-reader. The electrochemiluminescent platform ensures an
extremely sensitive detection and photons generated by Ruthenium (II) tris-2,2′-bipyridine-tag emit at a
longer wavelength (620 nM) than most natural products.
In 2011, an innovative spectrophotometric assay has been set up by Berndsen and Wolberger for
measuring ubiquitin transfer, without using tagged substrates or gel electrophoresis technique [119].
Even if this method has not been directly tested for screening of natural products mixtures, the
authors assess this method to be amenable for HTS approaches. The assay correlates ubiquitin
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transfer by E2 and E3 to the E1-Ub intermediate formation; this is an ATP-dependent reaction
releasing pyrophosphate, which subsequently undergoes hydrolysis to yield inorganic phosphate by a
pyrophosphatase added in the assay solution. The inorganic phosphate is quantified by measuring the
absorbance of molybdenum blue, a phosphomolybdate complex, that is formed from free phosphate
by adding molybdate in the presence of ascorbic acid. For HTS applications, a plate reader capable of
measuring molybdenum blue absorbance between 660 nm and 850 nm is needed.
HTS assays to evaluate proteolytic activity of DUBs enzymes have been developed along years,
too. Many procedures currently in use rely on cleavage of linear Ub or small peptides mimicking the
C-terminal part of Ub, fused to a fluorogenic substrate (e.g., AMC). In order to monitor deconjugation
of Ub by USP7 during fractionation of sponge extracts, Yamaguchi and colleagues employed a
recombinant USP7 protein and Ubiquitin-rhodamine 110 as quenched, fluorescent substrate [78].
USP7-cleavage of the amide bond between the C-terminal glycine of Ub and rhodamine results
in an increase in rhodamine fluorescence at 535 nm (excitation wavelength 485 nm). In addition,
Goldenberg et al. developed an HTS assay platform consisting of Ub fused to the reporter enzyme
PLA2 (phospholipase A2) [120]. Isopeptidase activity of DUBs releases active PLA2 that cleaves its
substrate, giving a readily quantifiable fluorescent response. The phospholipid β-BODIPY C5-HPC
[2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-
phosphocholine] and sphingolipid NBD C6-HPC {2-[6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-amino]
hexanoyl-1-hexadecanoyl-sn-glycero-3-phosphocholine} are fluorescent substrates commonly used for
this assay, producing a fluorescence response over a wavelength range (500–650 nM) outside the UV
range where most natural leads are able to emit.
6.3. Indirect Methods to Detect Natural Products Targeting the UPP Pathways
Differently from the above described approaches to isolate natural products blocking specific
targets, several other non-specific methods have been developed to detect bioactive compounds
through evaluation of downstream effects produced by UPP inhibition in cell-based systems. These
methods allow to observe alterations of substrate levels which can be related either to a selective
inhibition of an unknown target within the UPP pathway or to a broader variety of drug-induced
mechanisms. When conglomerates are screened, trace-amount compounds risk to be overlooked due
the detection limits of these approaches. Moreover, in some cases drug-treatment does not necessarily
produce significant alterations in cellular responses even if the compound inhibits the UPP pathway
at some point. Therefore, unspecific screening methods are usually recommended to support and
complement target-oriented isolation of bioactive natural products from crude extracts. The main
advantage of indirect methods can be found in the potential detection of compounds which are able to
cross cell membrane and produce a certain cellular effect.
Inhibition of the UPP may result in accumulation of polyubiquitinated proteins. Ub accumulation
assays allow to measure levels of Ub-labeled substrates within mammalian cell lines after
drug-exposure [60,77]. After treatment, cell lysates are separated through SDS PAGE and ubiquitinated
proteins are visualized by Western blotting analyses. Alternatively, UPP proteolytic activity can be
monitored by measuring cellular degradation of Ub-tagged reporter proteins after treatment with
a pure compound or an heterogenous sample. These assays rely on the use of transfected cell lines
harboring a stable expression system encoding for the fusion construct Ub-green fluorescent protein
(Ub-GFP) or Ub-luciferase [121,122]. Accumulation of the reporter protein due to decreased UPP
digestion capacity can be measured by either spectrophotometry or fluorescence microscopy. In 2018,
Ling and colleagues validated a novel, sensitive high-content screening assay to monitor aggregations
of ubiquitinated proteins within cells expressing the human cytomegalovirus protein EGFP-UL76. This
method is based upon high-content measurements of EGFP-UL76 aggresome formation by fluorescence
imaging [68].
Screening techniques have been also addressed to quantify specific proteasomal substrates
other than Ub. As explained above, impairing proteasomal activity usually leads to inhibition of
Mar. Drugs 2018, 16, 467 29 of 37
IkB degradation and inactivation of the nuclear factor NF-κB as well as to stabilization of tumor
suppressor factors, such as p53. Therefore, measurements of cellular IkB or p53 concentration levels by
immunoblotting have been regarded as valuable approaches to discover UPP inhibitors [59,82].
7. Conclusions and Perspectives
The UPP pathway is the main regulator of protein turnover in eukaryotic cells, and its therapeutic
modulation through proteasome inhibition has represented a definite step forward in treatment of
hematological malignancies. Impairing proteasome activity in cancer cells has provided the chance to
shift the fine balance between protein synthesis and degradation towards cell death, as demonstrated
by recent introduction of bortezomib and carfilzomib in clinical settings.
Marine sources have been demonstrated to be an unexhaustive factory of UPP inhibitors, covering
a wide chemical space. During the last decade, most of marine UPP inhibitors have been isolated from
sponges or sponge-associated microorganisms (Figure 5a).
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Even if the majority of resistance mechanisms to proteasome inhibitors remains yet unknown,
several studies unveiled putative pathways hampering successful outcomes of proteasome
inhibition-based therapy. In this contest, combination regimens have been tested in order to overcome
resistance and sensitize cancer cells to proteasome inhibition. On the basis of the complementary
effects on signal transduction and protein regulatory pathways, combining proteasome and histone
deacetylase (HDAC) i hibition has provided a synergistic anti-tumor eff ct in tumor cell lines from
patients with melanoma, pancreatic, and lung c ncer after o dministr tion of salinosporamide A and
v rinostat (a FDA approved HDAC inhibitor) [49]. Overall, another potential appro ch could be to
desig a ‘dual inhibitor’, which blocks at the same time the pr teasome and the pa way responsible
for resistance to prot as me inhibition. If this may appear too challenging from a chemical-synthesis
perspective, natural products have been already shown to act as potential ‘dual inhibitors’ in some cases.
The robust pan-proteasome inhibition by salinosporamide A overcame successfully the resistance
mechanism triggered by the residual β2 proteolytic activity [51], which makes solid tumors refractory
to treatment with bortezomib/carfilzomib. Moreover, largazole has been demonstrated to inhibit
both the ubiquitin-proteasome pathway and the HDAC, thereby providing the basis for a synergistic
anti-tumor effect.
Beyond the proteasome, the UPP has multiple other druggable targets, such as E1, E2, E3,
and DUBs. The majority of the reviewed molecules have been shown to act mainly against the
proteasome, highlighting that identification of drugs that specifically inhibit deubiquitinases and
upstream regulatory components of the protein-turnover machinery has lagged behind (Figure 5b).
However, a future perspective can be found in the discovery of new compounds targeting effectors of
the ubiquitin cascade other than proteasome, as these molecules might show antitumor activity alone,
and/or synergistic cytotoxic effects. Notably, it is worth mentioning that variabines feature a simple
β-carboline moiety which allow them to repress both the chymotrypsin-like activity of the proteasome
and the Ubc13–Uev1A int raction. Simila ly, halenaquinone was shown to act as a deubiquitinase and
a proteasome inhibitor at the same time.
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Differently from proteasome or E1 inhibitors, selective inhibition of a certain isoform of E2, E3,
or DUB enzymes has the potential to target a limited set of substrates and modulate the specific
pathway regulated by that enzyme, thereby leading to fewer side effects and a more suitable
targeted therapy [35]. As an example, blocking exclusively MDM2 among the 600 known E3 ligases
leads to stabilization of the tumor suppressor factor p53, as MDM2 is the main regulator of p53
cellular degradation.
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